{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:16:11Z","timestamp":1790882171928,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Research Foundation of Korea (NRF) grant funded by the Korea government","award":["NRF-2020R1C1C1013766"],"award-info":[{"award-number":["NRF-2020R1C1C1013766"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The association between nonalcoholic fatty liver (NAFL) or liver fibrosis and diabetic peripheral neuropathy (DPN) has not been well studied. We aimed to investigate the association of NAFL or liver fibrosis indices and DPN in individuals with type 2 diabetes. In this observational study, we included 264 individuals with type 2 diabetes, and calculated non-alcoholic fatty liver disease (NAFLD) liver fat score, NAFLD fibrosis score, and Fibrosis-4 (FIB-4) index to evaluate the status of NAFLD or liver fibrosis. DPN was diagnosed when the Michigan Neuropathy Screening Instrument\u2014Physical Examination score was\u2009\u2265\u20092.5. The NAFLD fibrosis score and FIB-4 index were significantly higher in individuals with DPN than in those without DPN. Logistic analyses showed that the NAFLD fibrosis score and FIB-4 index were associated with DPN after adjustment for covariates (adjusted odds ratio 1.474 and 1.961, respectively). In the subgroup analysis, this association was only significant in the group with a high NAFLD liver fat score (&gt;\u2009\u2212\u20090.640). Serum levels of fetuin-A, a hepatokine, were decreased in individuals with abnormal vibration perception or 10-g monofilament tests compared with their counterparts. The present study suggests that liver fibrosis might be associated with DPN in individuals with type 2 diabetes.<\/jats:p>","DOI":"10.1038\/s41598-021-03870-z","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T11:03:53Z","timestamp":1640084633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes"],"prefix":"10.1038","volume":"11","author":[{"given":"Kyuho","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jung","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyen Chung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ho","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Kyung","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak Chul","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"3870_CR1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz009","author":"T Marjot","year":"2020","unstructured":"Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L. & Tomlinson, J. W. Nonalcoholic fatty liver disease in adults: Current concepts in etiology, outcomes, and management. Endocr. Rev. https:\/\/doi.org\/10.1210\/endrev\/bnz009 (2020).","journal-title":"Endocr. Rev."},{"key":"3870_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330\u2013344. https:\/\/doi.org\/10.1038\/nrgastro.2013.41 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"3870_CR3","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J. Hepatol. 62, 1148\u20131155. https:\/\/doi.org\/10.1016\/j.jhep.2014.11.034 (2015).","journal-title":"J. Hepatol."},{"key":"3870_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/hep.510290347","volume":"29","author":"SH Caldwell","year":"1999","unstructured":"Caldwell, S. H. et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 29, 664\u2013669. https:\/\/doi.org\/10.1002\/hep.510290347 (1999).","journal-title":"Hepatology"},{"key":"3870_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.cgh.2009.06.007","volume":"7","author":"N Hossain","year":"2009","unstructured":"Hossain, N. et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1224\u20131229. https:\/\/doi.org\/10.1016\/j.cgh.2009.06.007 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"3870_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4093\/dmj.2020.0010","volume":"44","author":"BW Lee","year":"2020","unstructured":"Lee, B. W. et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the fatty liver research group of the Korean diabetes association. Diabetes Metab. J. 44, 382\u2013401. https:\/\/doi.org\/10.4093\/dmj.2020.0010 (2020).","journal-title":"Diabetes Metab. J."},{"key":"3870_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154752","volume":"121","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo, S. & Perseghin, G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism 121, 154752. https:\/\/doi.org\/10.1016\/j.metabol.2021.154752 (2021).","journal-title":"Metabolism"},{"key":"3870_CR8","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2337\/dc07-0349","volume":"30","author":"G Targher","year":"2007","unstructured":"Targher, G. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30, 2119\u20132121. https:\/\/doi.org\/10.2337\/dc07-0349 (2007).","journal-title":"Diabetes Care"},{"key":"3870_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2337\/dc06-2247","volume":"30","author":"G Targher","year":"2007","unstructured":"Targher, G. et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30, 1212\u20131218. https:\/\/doi.org\/10.2337\/dc06-2247 (2007).","journal-title":"Diabetes Care"},{"key":"3870_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","volume":"51","author":"G Targher","year":"2008","unstructured":"Targher, G. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51, 444\u2013450. https:\/\/doi.org\/10.1007\/s00125-007-0897-4 (2008).","journal-title":"Diabetologia"},{"key":"3870_CR11","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1681\/ASN.2007101155","volume":"19","author":"G Targher","year":"2008","unstructured":"Targher, G. et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 19, 1564\u20131570. https:\/\/doi.org\/10.1681\/ASN.2007101155 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3870_CR12","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0118","author":"E Han","year":"2021","unstructured":"Han, E., Kim, M. K., Jang, B. K. & Kim, H. S. Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab. J https:\/\/doi.org\/10.4093\/dmj.2020.0118 (2021).","journal-title":"Diabetes Metab. J"},{"key":"3870_CR13","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye, S. et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33, 2285\u20132293. https:\/\/doi.org\/10.2337\/dc10-1303 (2010).","journal-title":"Diabetes Care"},{"key":"3870_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1900\/RDS.2015.12.48","volume":"12","author":"N Papanas","year":"2015","unstructured":"Papanas, N. & Ziegler, D. Risk factors and comorbidities in diabetic neuropathy: An update 2015. Rev. Diabet. Stud. 12, 48\u201362. https:\/\/doi.org\/10.1900\/RDS.2015.12.48 (2015).","journal-title":"Rev. Diabet. Stud."},{"key":"3870_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1530\/EJE-11-0864","volume":"166","author":"JW Haukeland","year":"2012","unstructured":"Haukeland, J. W. et al. Fetuin a in nonalcoholic fatty liver disease: In vivo and in vitro studies. Eur. J. Endocrinol. 166, 503\u2013510. https:\/\/doi.org\/10.1530\/EJE-11-0864 (2012).","journal-title":"Eur. J. Endocrinol."},{"key":"3870_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jdiacomp.2017.01.024","volume":"31","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J. Diabetes Complicat 31, 1021\u20131026. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.01.024 (2017).","journal-title":"J. Diabetes Complicat"},{"key":"3870_CR17","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.3748\/wjg.v19.i20.3134","volume":"19","author":"WS Lv","year":"2013","unstructured":"Lv, W. S. et al. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J. Gastroenterol. 19, 3134\u20133142. https:\/\/doi.org\/10.3748\/wjg.v19.i20.3134 (2013).","journal-title":"World J. Gastroenterol."},{"key":"3870_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/jdi.12139","volume":"5","author":"BY Kim","year":"2014","unstructured":"Kim, B. Y., Jung, C. H., Mok, J. O., Kang, S. K. & Kim, C. H. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J. Diabetes Investig. 5, 170\u2013175. https:\/\/doi.org\/10.1111\/jdi.12139 (2014).","journal-title":"J. Diabetes Investig."},{"key":"3870_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jdiacomp.2015.06.015","volume":"29","author":"KH Williams","year":"2015","unstructured":"Williams, K. H. et al. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. J. Diabetes Complicat. 29, 1240\u20131247. https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.06.015 (2015).","journal-title":"J. Diabetes Complicat."},{"key":"3870_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154299","volume":"111S","author":"B Dewidar","year":"2020","unstructured":"Dewidar, B., Kahl, S., Pafili, K. & Roden, M. Metabolic liver disease in diabetes: From mechanisms to clinical trials. Metabolism 111S, 154299. https:\/\/doi.org\/10.1016\/j.metabol.2020.154299 (2020).","journal-title":"Metabolism"},{"key":"3870_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41574-021-00496-z","volume":"17","author":"G Sloan","year":"2021","unstructured":"Sloan, G., Selvarajah, D. & Tesfaye, S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat. Rev. Endocrinol. 17, 400\u2013420. https:\/\/doi.org\/10.1038\/s41574-021-00496-z (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"3870_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4093\/dmj.2017.0105","volume":"42","author":"SY Rhee","year":"2018","unstructured":"Rhee, S. Y. & Kim, Y. S. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab. J. 42, 188\u2013195. https:\/\/doi.org\/10.4093\/dmj.2017.0105 (2018).","journal-title":"Diabetes Metab. J."},{"key":"3870_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1210\/en.2006-0073","volume":"148","author":"AM Vincent","year":"2007","unstructured":"Vincent, A. M. et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 148, 548\u2013558. https:\/\/doi.org\/10.1210\/en.2006-0073 (2007).","journal-title":"Endocrinology"},{"key":"3870_CR24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/j.1440-1746.2007.04943.x","volume":"22","author":"H Hyogo","year":"2007","unstructured":"Hyogo, H. et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22, 1112\u20131119. https:\/\/doi.org\/10.1111\/j.1440-1746.2007.04943.x (2007).","journal-title":"J Gastroenterol Hepatol"},{"key":"3870_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00535-007-2152-7","volume":"43","author":"K Iwamoto","year":"2008","unstructured":"Iwamoto, K. et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 43, 298\u2013304. https:\/\/doi.org\/10.1007\/s00535-007-2152-7 (2008).","journal-title":"J Gastroenterol"},{"key":"3870_CR26","doi-asserted-by":"publisher","first-page":"E266","DOI":"10.1152\/ajpendo.00262.2017","volume":"314","author":"A Peter","year":"2018","unstructured":"Peter, A. et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am. J. Physiol. Endocrinol. Metab. 314, E266\u2013E273. https:\/\/doi.org\/10.1152\/ajpendo.00262.2017 (2018).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"3870_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01392-5","author":"I Barchetta","year":"2020","unstructured":"Barchetta, I. et al. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD\/NASH in individuals with and without obesity and metabolic disease. J. Endocrinol. Invest. https:\/\/doi.org\/10.1007\/s40618-020-01392-5 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"3870_CR28","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/liv.12478","volume":"35","author":"M Sato","year":"2015","unstructured":"Sato, M. et al. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int 35, 925\u2013935. https:\/\/doi.org\/10.1111\/liv.12478 (2015).","journal-title":"Liver Int"},{"key":"3870_CR29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jdiacomp.2009.07.007","volume":"24","author":"J Ybarra","year":"2010","unstructured":"Ybarra, J., Pou, J. M., Romeo, J. H., Merce, J. & Jurado, J. Transforming growth factor beta 1 as a biomarker of diabetic peripheral neuropathy: Cross-sectional study. J. Diabetes Complicat. 24, 306\u2013312. https:\/\/doi.org\/10.1016\/j.jdiacomp.2009.07.007 (2010).","journal-title":"J. Diabetes Complicat."},{"key":"3870_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740\u2013751. https:\/\/doi.org\/10.1038\/ajg.2016.453 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"3870_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","volume":"158","author":"K Bush","year":"1998","unstructured":"Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D. & Bradley, K. A. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch. Intern. Med. 158, 1789\u20131795. https:\/\/doi.org\/10.1001\/archinte.158.16.1789 (1998).","journal-title":"Arch. Intern. Med."},{"key":"3870_CR32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883 (1985).","journal-title":"Diabetologia"},{"key":"3870_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2337\/diacare.17.11.1281","volume":"17","author":"EL Feldman","year":"1994","unstructured":"Feldman, E. L. et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17, 1281\u20131289. https:\/\/doi.org\/10.2337\/diacare.17.11.1281 (1994).","journal-title":"Diabetes Care"},{"key":"3870_CR34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1464-5491.2012.03644.x","volume":"29","author":"WH Herman","year":"2012","unstructured":"Herman, W. H. et al. Use of the michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: Results from the diabetes control and complications trial\/epidemiology of diabetes interventions and complications. Diabet Med. 29, 937\u2013944. https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03644.x (2012).","journal-title":"Diabet Med."},{"key":"3870_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0168-8227(98)00005-9","volume":"39","author":"M Lunetta","year":"1998","unstructured":"Lunetta, M., Le Moli, R., Grasso, G. & Sangiorgio, L. A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy. Diabetes Res. Clin. Pract. 39, 165\u2013172. https:\/\/doi.org\/10.1016\/s0168-8227(98)00005-9 (1998).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"3870_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3803\/EnM.2016.31.2.230","volume":"31","author":"JC Won","year":"2016","unstructured":"Won, J. C. & Park, T. S. Recent advances in diagnostic strategies for diabetic peripheral neuropathy. Endocrinol. Metab. (Seoul) 31, 230\u2013238. https:\/\/doi.org\/10.3803\/EnM.2016.31.2.230 (2016).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"3870_CR37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","volume":"137","author":"A Kotronen","year":"2009","unstructured":"Kotronen, A. et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137, 865\u2013872. https:\/\/doi.org\/10.1053\/j.gastro.2009.06.005 (2009).","journal-title":"Gastroenterology"},{"key":"3870_CR38","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846\u2013854. https:\/\/doi.org\/10.1002\/hep.21496 (2007).","journal-title":"Hepatology"},{"key":"3870_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard, A. et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46, 32\u201336. https:\/\/doi.org\/10.1002\/hep.21669 (2007).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03870-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:34:54Z","timestamp":1670092494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03870-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3870"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03870-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24372"}}